PCI Pharma’s Bedford Facility Passes ICMRA Inspection, First CDMO to Succeed under CHIP Program

The International Coalition of Medicines Regulatory Authorities (ICMRA) has successfully concluded its inspection of PCI Pharma Services' (PCI), a worldwide contract development and manufacturing organisation (CDMO) Bedford, New Hampshire site.

By achieving this, PCI becomes the first CDMO for drug products to successfully pass the multi-agency inspection procedure. This is a feature of the Collaborative Hybrid Inspection Pilot (CHIP) program, a new initiative from the ICMRA that focusses on mutual assessment of facilities within its jurisdiction that manufacture medicines.